Please use this identifier to cite or link to this item:
Title: Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine.
Austin Authors: Litt, John;Booy, Robert;Bourke, Debra;Dwyer, Dominic E;Leeb, Alan;McCloud, Philip;Stein, Alicia N;Woodward, Michael M ;Cunningham, Anthony L
Affiliation: Discipline of General Practice College of Medicine and Public Health, Flinders University, Adelaide, Australia
NSW Health Pathology - Institute for Clinical Pathology and Medical Research, Westmead Hospital and the University of Sydney, Sydney, Australia
Medical Department, Seqirus (Australia) Pty Ltd, Parkville, Australia
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney, Sydney, Australia
Faculty of Medicine and Health, The Westmead Institute for Medical Research, Westmead, Australia
The University of Sydney, Sydney, Australia
Centre for Virus Research, University of Melbourne, Melbourne, Australia
Helath Economics, Seqirus (Australia) Pty Ltd, Parkville, Australia
McCloud Consulting Group, Belrose, Australia
Illawarra Medical Centre, Ballajura, Australia
Department of Aged and Continuing Care, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 1-Dec-2020
Date: 2020-05-18
Publication information: Human Vaccines & Immunotherapeutics 2020; 16(12): 3081-3089
Abstract: Herpes zoster (shingles) is a painful condition resulting from reactivation of latent varicella zoster virus (VZV). The Australian National Shingles Vaccination Program (commenced November 2016) provides free herpes zoster vaccination for eligible adults aged 70 years, with a 5-year catch-up program (until October 2021) for adults aged 71-79 years. Patterns and impact of the program were evaluated by analysis of vaccine distribution and delivery data and specific antiviral prescription data from the Pharmaceutical Benefits Scheme. During the first 2 years, uptake of funded live attenuated shingles vaccine ZOSTAVAX® (Zoster Virus Vaccine Live; ZVL) was high across the ongoing and catch-up programs. Before program implementation (2006-2016), herpes zoster coded antiviral prescription rates increased by 2.2% per year (95% CI: 1.5, 2.9) in the 70-79 years age group. In the two years since program launch, herpes zoster antiviral prescription rates declined substantially in this age group, by an average of 13.6% per year (95% CI: 1.5, 24.2). These results indicate that the National Shingles Vaccination Program has been highly successful in vaccinating a considerable proportion of Australian adults aged 70-79 years against herpes zoster and suggest that vaccine uptake was associated with decreased incidence of herpes zoster.
DOI: 10.1080/21645515.2020.1754702
ORCID: 0000-0002-6744-5667
Journal: Human Vaccines & Immunotherapeutics
PubMed URL: 32420793
Type: Journal Article
Subjects: Herpes zoster
herpes zoster vaccine
postherpetic neuralgia
varicella zoster virus
zoster virus vaccine live
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 30, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.